Accelovance’s Stephen Trevisan And Robert deGroof On China’s Clinical Research Landscape: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Accelovance CEO Stephen Trevisan and Chief Scientific Officer Robert deGroof recently spoke with PharmAsia News about the evolving landscape for conducting clinical trials in China. Accelovance, based in Rockville, Md., has 10 clinical sites in the U.S. and a wholly owned enterprise in China with offices in Beijing and Shanghai to provide International Conference on Harmonization-good clinical practices compliant clinical trials.
You may also be interested in...
Chinese Health Care Reform: Market Opportunities And Challenges
China's renewed emphasis on reforming its health care system is creating both opportunities and challenges for foreign manufacturers doing business there, according to speakers at AdvaMed's 2008 MedTech Conference in Washington, D.C
Chinese Health Care Reform: Market Opportunities And Challenges
China's renewed emphasis on reforming its health care system is creating both opportunities and challenges for foreign manufacturers doing business there, according to speakers at AdvaMed's 2008 MedTech Conference in Washington, D.C
Accelovance’s Stephen Trevisan And Robert deGroof On China’s Clinical Research Landscape: An Interview With PharmAsia News (Part 2 of 2)
[Editor's Note: This is part two of a two-part interview. Part one appeared in PharmAsia News, May 15, 2008.]